kpv 20mg

Overview of KPV 20mg in Preclinical Research

KPV 20mg represents a standardized 20-milligram quantity of the tripeptide Lysine-Proline-Valine (Lys-Pro-Val), a active fragment corresponding to amino acids 11–13 of the endogenous neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH). In preclinical investigations, KPV exhibits potent anti-inflammatory properties without triggering the melanogenic responses associated with full-length alpha-MSH or broader melanocortin receptor agonists.

Researchers evaluating kpv 20mg focus primarily on its intracellular signaling mechanisms, epithelial uptake kinetics, and regulatory effects on mucosal cytokine expression. Because KPV lacks the central His-Phe-Arg-Trp core sequence necessary for activating classical melanocortin receptors (MC1R–MC5R) to induce pigment synthesis, it serves as a precise tool for isolating alpha-MSH-derived anti-inflammatory pathways from systemic endocrine responses.

To maintain reproducibility in biochemical assays and animal models, laboratory researchers require high-purity reagents. PX1 Research supplies kpv 20mg at >99% purity as determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and electrospray ionization mass spectrometry (ESI-MS). Every batch undergoes rigorous quality control to ensure strict adherence to physical and chemical parameters suitable for in vitro cell cultures and in vivo rodent research.

Molecular Structure and Cellular Uptake Dynamics

The molecular formula of KPV is C16H30N4O4, with a nominal molecular weight of 342.44 g/mol. Despite its small molecular mass, the tripeptide sequence exhibits distinct structural features that dictate its stability and cellular bioavailability. The proline residue imparts conformational rigidity, protecting the peptide bond from rapid enzymatic cleavage by non-specific aminopeptidases in biological media.

A critical finding in epithelial research is that KPV enters target cells through active transport mechanisms rather than passive transcellular diffusion alone. In intestinal epithelial cells, KPV serves as a substrate for the solute carrier family 15 member 1 (SLC15A1), commonly known as the Peptide Transporter 1 (PepT1). PepT1 is expressed on the apical membrane of enterocytes and is frequently upregulated during active intestinal inflammation.

Preclinical data indicate that PepT1-mediated endocytosis facilitates the direct intracellular accumulation of KPV. Once inside the cytoplasm, KPV interacts with intracellular target proteins to interrupt signaling cascades responsible for inflammatory gene transcription. Understanding these transport dynamics allows investigators to model targeted mucosal delivery mechanisms using intestinal barrier peptides in controlled laboratory environments.

Intracellular Signaling: NF-kB Modulation and Cytokine Regulation

At the molecular level, the primary anti-inflammatory mechanism of KPV involves the inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway. In unstimulated cells, NF-kB heterodimers (typically p50/p65) are sequestered in the cytoplasm by the inhibitor protein I-kB. Upon exposure to pro-inflammatory stimuli such as lipopolysaccharide (LPS), tumor necrosis factor-alpha (TNF-alpha), or interleukin-1 beta (IL-1beta), I-kB undergoes phosphorylation and degradation, allowing NF-kB to translocate into the nucleus.

In vitro assays using enterocytes, macrophages, and dendritic cells demonstrate that KPV treatment blocks the translocation of the NF-kB p65 subunit into the cell nucleus. By directly interfering with the nuclear import machinery or stabilizing cytosolic complexes, KPV prevents NF-kB from binding to specific promoter regions of pro-inflammatory genes.

As a result of this transcriptional blockade, experimental models treated with KPV exhibit marked reductions in downstream inflammatory mediators, including interleukin-6 (IL-6), interleukin-8 (IL-8), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2). Research published in peer-reviewed literature confirms that these anti-inflammatory effects occur at nanomolar to micromolar concentrations, establishing KPV as a highly sensitive reagent for cell signaling assays.

Investigating KPV in Intestinal Barrier and Colitis Models

Dysfunction of the intestinal epithelial barrier is a hallmark of gastrointestinal pathology, characterized by the breakdown of tight junction complexes and increased paracellular permeability. Preclinical colitis research frequently utilizes chemical agents such as dextran sulfate sodium (DSS) or 2,4,6-trinitrobenzenesulfonic acid (TNBS) to induce acute mucosal injury and inflammation in rodent models.

When administered in preclinical animal models of DSS-induced colitis, KPV has been shown to attenuate body weight loss, reduce disease activity index (DAI) scores, and decrease histological damage within the colonic tissue. Mechanistic evaluations reveal that KPV preserves the structural expression of key tight junction proteins, including zonula occludens-1 (ZO-1), occludin, and claudin family members.

Furthermore, comparative studies highlight that KPV can be encapsulated in specialized nanoparticle carriers or hyaluronic acid-based hydrogels to evaluate localized colonic delivery. Investigators exploring mucosal healing pathways often cross-reference KPV data with findings from other alpha-MSH analogs and tissue repair molecules available across the broader PX1 catalog of research peptides.

Comparative Analysis: KPV, BPC-157, and LL-37 in Epithelial Research

When designing protocols to analyze mucosal protection, tissue repair, or antimicrobial defense, researchers frequently evaluate KPV alongside related peptide compounds. While all these agents modulate cellular responses within epithelial tissues, their primary molecular targets and structural profiles differ significantly.

KPV functions predominantly as a targeted intracellular modulator of NF-kB signaling and PepT1 transport. In contrast, pentadecapeptide BPC-157 5mg acts primarily through the upregulation of growth factors (such as VEGF and bFGF), nitric oxide pathway regulation, and focal adhesion kinase (FAK) activation to stimulate angiogenesis and tissue remodeling. Meanwhile, antimicrobial peptide LL-37 exerts direct membrane-disrupting activity against pathogens while activating formyl peptide receptors (FPRL1) to recruit immune cells.

By comparing KPV 20mg with BPC-157 5mg and cathelicidin derivatives like LL-37, laboratories can isolate specific variables—such as direct transcriptional suppression versus growth factor signaling—in complex inflammation models. For broader musculoskeletal and tissue structural studies, investigators may also include TB-500 in multi-agent comparative matrices.

Quality Standards and Analytical Verification for KPV 20mg

In scientific research, minor impurities, peptide fragments, or residual organic solvents can distort binding kinetics, alter cellular viability assays, and invalidate experimental outcomes. PX1 Research enforces an uncompromising quality assurance standard for every lot of kpv 20mg distributed to scientific institutions.

Each batch is synthesized in USA-based, ISO 17025-accredited and GMP-compliant facilities utilizing advanced solid-phase peptide synthesis (SPPS) technology. Following cleavage and purification, the raw peptide undergoes dual analytical validation:

1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Establishes chemical purity, verifying that the main peak accounts for at least 99.0% of total integrated UV absorbance. 2. Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact monoisotopic mass, ensuring correct sequence alignment and complete absence of truncated synthetic fragments.

Additionally, all lots undergo kinetic chromogenic LAL assays to verify that bacterial endotoxin levels remain strictly below <0.01 EU/mg. Every single shipment includes a lot-specific Certificate of Analysis (COA) accessible directly through our PX1 Research Hub.

Laboratory Handling, Reconstitution, and Storage Protocols

To preserve the chemical stability and biological activity of KPV 20mg, research personnel must adhere to standardized handling and reconstitution protocols upon receiving the product:

Lyophilized Storage: Upon delivery, unopened vials containing lyophilized KPV powder should be stored in a dry, dark location at -20°C for short-to-medium-term stability, or at -80°C for extended archival preservation. Minimize exposure to ambient light and moisture.

Reconstitution Procedures: Prior to opening, allow the glass vial to equilibrate to room temperature to prevent atmospheric condensation on the cake. Under a laminar flow hood, reconstitute the 20mg cake using sterile, laboratory-grade solvent—such as 0.9% sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4)—depending on specific assay parameters.

Solution Storage and Aliquoting: Once dissolved, gently swirl the vial until the solution is completely clear; avoid vigorous vortexing, which can induce physical shear stress. To prevent degradation caused by repeated freeze-thaw cycles, divide the stock solution into single-use microcentrifuge aliquots. Store reconstituted liquid aliquots at -20°C for up to 30 days or -80°C for up to 6 months.

Sourcing High-Purity KPV 20mg for Institutional Accounts

Principal investigators, academic laboratories, and biotechnology research centers require reliable, batch-consistent peptide supplies to support long-term research projects. PX1 Research prioritizes supply-chain integrity, offering immediate stock availability and rapid turnaround times.

All orders placed Monday through Friday ship same-day directly from our domestic distribution facilities in California and Arizona. Vials are packaged in temperature-monitored, shock-resistant containers to preserve physical integrity throughout transit.

For high-throughput screening projects, animal study cohorts, or multi-department research programs requiring large-scale peptide procurement, institutions can establish a dedicated wholesale lab account. Verified research buyers gain access to volume pricing tiers, batch reservation services, and customized analytical documentation for regulatory filing support.

Technical Specifications Summary for KPV 20mg

The following parameters define the structural, chemical, and physical baseline of PX1 Research KPV 20mg:

• Sequence: Lysine-Proline-Valine (Lys-Pro-Val / KPV) • CAS Number: 67727-97-3 • Molecular Formula: C16H30N4O4 • Molecular Weight: 342.44 g/mol • Physical Form: Sterile lyophilized white powder • Purity Grade: >99.0% (Verified by RP-HPLC) • Mass Identification: Confirmed via ESI-MS • Endotoxin Limit: <0.01 EU/mg • Sourcing: Manufactured in USA (GMP-Compliant, ISO 17025 Facility) • Format: 20mg sealed glass vial • Intended Use: Strictly for laboratory in vitro and preclinical research applications